References
- Dixit R, Matthews S, Khandaker G, et al. Pharmacokinetics of oseltamivir in infants under the age of 1 year. Clin Transl Med. 2016;5:37.
- Chen WH, Lu CY, Shao PL, et al. Risk factors of severe novel influenza A (H1N1) infections in hospitalized children. J Formos Med Assoc. 2012;111(8):421–426.
- Srinivas NR. Influence of morbidly obesity on the clinical pharmacokinetics of various anti-infective drugs: reappraisal using recent case studies-issues, dosing implications, and considerations. Am J Ther. 2018;25(2):e224–e246.
- Ohno Y, Miyoshi T, Noda Y, et al. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovasc Diabetol. 2014;13(1):71.
- Noe N, Dillon L, Lellek V, et al. RETRACTED: bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy. Mitochondrion. 2013;13(5):417–426.
- Toovey S, Prinssen EP, Rayner CR, et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther. 2012;29(10):826–848.
- Yoshino T, Nisijima K, Shioda K, et al. Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex. Neurosci Lett. 2008;438(1):67–69.
- Oshima S, Nemoto E, Kuramochi M, et al. Penetration of oseltamivir and its active metabolite into the brain after lipopolysaccharide-induced inflammation in mice. J Pharm Pharmacol. 2009;61(10):1397–1400.
- Benuck M, Banay-Schwartz M, DeGuzman T, et al. Effect of food deprivation on glutathione and amino acid levels in brain and liver of young and aged rats. Brain Res. 1995;678(1-2):259–264.
- Katarzyna A, Anne R, Neil H. S-Nitrosoglutathione. Biochim Biophys Acta. 2013;1830(5):31173–33181.
- Stricker KA, Beck B, Burlet C. Nitric oxide mediates hyperphagia of obese Zucker rats: relation to specific changes in the microstructure of feeding behavior. Life Sci. 1996;58:9–15.
- Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxides. Proc Natl Acad Sci USA. 1990;87:1624–1629.
- Swapna I, Sathya KV, Murthy CR. Membrane alterations and fluidity changes in cerebral cortex during ammonia intoxication. Neurotoxicology. 2005;335:700–704.
- Neault JF, Benkiran A, Malonga H, et al. The effects of anions on the solution structure of Na,K-ATPase. J Biomol Struct Dyn. 2001;19(1):95–102.
- Calderón GD, Labra RN, Hernández GE, et al. Effect of sibutramine on Na+, K+ ATPase activity and tryptophan levels on male and female rat brain. Horm Metab Res. 2009;41:363–367.
- Calderon GD, Juárez OH, Hernández GE, et al. Mechanisms of prooxidants in neuroinflammatory processes and clinical manifestations. Ann Res Rev Biol. 2014;4:3949–3961.
- Calderón Guzmán D, Juárez Olguín H, Hernández Garcia E, et al. Effect of an antiviral and vitamins a, c, d on dopamine and some oxidative stress markers in rat brain exposed to ozone. Arch Biol Sci (Beogr)). 2013;65(4):1371–1379.
- Beck O, Palmskog G, Hultman E. Quantitative determination of 5-hydroxyindole-3-acetic acid in body fluids by HPLC. Clin Chim Acta. 1977;79(1):149–154.
- Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem. 1976;74(1):214–226.
- Calderón-Guzmán D, Espitia-Vázquez I, López-Domínguez A, et al. Effect of toluene and nutritional status on serotonin, lipid peroxidation levels and Na+/K+-ATPase in adult rat brain. Neurochem Res. 2005;30(5):619–624.
- Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem. 1925;66:375–400.
- Asru KS. Colorimetric assay of catalase. Anal Biochem. 1972;47:389–394.
- Gutteridge JM, Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci. 1990;15(4):129–135.
- Castilla-Serna L. Practical statistical manual for health sciences. 1st ed. Mexico, D.F.: Editorial Trillas; 2011.
- Kido H, Indalao IL, Kim H, et al. Energy metabolic disorder is a major risk factor in severe influenza virus infection: Proposals for new therapeutic options based on animal model experiments. Respir Investig. 2016;54(5):312–319.
- Zafrir B, Jain M. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther. 2014;28(4):361–377.
- Academic Medicine Vademecum. Rodolfo rodriguez carranza. 6th ed. Mexico, D.F.: MC Graw Hill Editorial; 2013.
- Bandgar BP, Sarangdhar RJ, Fruthous K, et al. Synthesis and biological evaluation of ester prodrugs of benzafibrate as orally active hypolipidemic agents. Eur J Med Chem. 2012;57:217–224.
- Morimoto K, Nakakariya M, Shirasaka Y, et al. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-Glycoprotein. Drug Metab Dispos. 2008;36(1):6–9.
- Johanson CE. Permeability and vascularity of the developing brain: cerebellum vs cerebral cortex. Brain Res. 1980;190(1):3–16.
- Kacergius T, Ambrozaitis A, Deng Y, et al. Neuraminidase inhibitors reduce nitric oxide production in influenza virus-infected and gamma interferon-activated RAW 264.7 macrophages. Pharmacol Rep. 2006;58:924–930.
- Ju TC, Chen SD, Liu CC, Yang DI. Protective effects of S-nitrosoglutathione against amyloid beta-peptide neurotoxicity. Free Radic Biol Med. 2005;38(7):938–949.
- Fuke C, Ihama Y, Miyazaki T. Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu. Leg Med (Tokyo). 2008;10(2):83–87.
- Vardakas KZ, Theocharis G, Tansarli GS, et al. Impact of oseltamivir use on the reduction of complications in patients with influenza: a prospective study. Arch Virol. 2016;161(9):2511–2518.
- Brase DA. Is intracellular sodium involved in the mechanism of tolerance to opioid drugs? Med Hypotheses. 1990;32(3):161–167.